Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $771.7 million.

  • NewAmsterdam Pharma Co N.V's Cash & Equivalents rose 27.36% to $538.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.4 million, marking a year-over-year increase of 27.36%. This contributed to the annual value of $771.7 million for FY2024, which is 126.68% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Cash & Equivalents stood at $771.7 million for FY2024, which was up 126.68% from $340.4 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Cash & Equivalents' 5-year high stood at $771.7 million during FY2024, with a 5-year trough of $340.4 million in FY2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $467.7 million (2022), whereas its average is $526.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first dropped by 27.21% in 2023, then spiked by 126.68% in 2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Cash & Equivalents (Yearly) stood at $467.7 million in 2022, then declined by 27.21% to $340.4 million in 2023, then surged by 126.68% to $771.7 million in 2024.